38) This #LVEF reduction with treatment is distinct from the natural history of untreated #HCM, where LVEF<50% reflects a burnt-out fibrotic stage associated with significant mortality and morbidity 👉🔓https://t.co/NVG3xjkabF 👉🔓https://t.co/zpnuFN3Xdc h
RT @JACCJournals: Deeper insights into end-stage #cvHCM: 10-fold higher mortality among other key findings. Learn more: https://t.co/rNby1g…
RT @JACCJournals: Deeper insights into end-stage #cvHCM: 10-fold higher mortality among other key findings. Learn more: https://t.co/rNby1g…
RT @edurontoFF: .En #MCH las estrategias de tratamiento actuales (#CDI, Transplante) han bajado la mortalidad del estadio terminal -Consid…
Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction Although ES remains an important complication of HCM Primary prevention ICDs should be considered when EF is <50% https://t.co/Fgdnd0U4fd
.En #MCH las estrategias de tratamiento actuales (#CDI, Transplante) han bajado la mortalidad del estadio terminal -Considerar prevención primaria con CDI con FEVI<50% -Hay largos periodos de estabilidad, aun en estadio terminal con disfuncion de VI. h
RT @JACCJournals: Deeper insights into end-stage #cvHCM: 10-fold higher mortality among other key findings. Learn more: https://t.co/rNby1g…
RT @JACCJournals: Deeper insights into end-stage #cvHCM: 10-fold higher mortality among other key findings. Learn more: https://t.co/rNby1g…
RT @JACCJournals: Deeper insights into end-stage #cvHCM: 10-fold higher mortality among other key findings. Learn more: https://t.co/rNby1g…
RT @JACCJournals: Deeper insights into end-stage #cvHCM: 10-fold higher mortality among other key findings. Learn more: https://t.co/rNby1g…
RT @JACCJournals: Deeper insights into end-stage #cvHCM: 10-fold higher mortality among other key findings. Learn more: https://t.co/rNby1g…
RT @JACCJournals: Deeper insights into end-stage #cvHCM: 10-fold higher mortality among other key findings. Learn more: https://t.co/rNby1g…
Deeper insights into end-stage #cvHCM: 10-fold higher mortality among other key findings. Learn more: https://t.co/rNby1gef7R @TuftsMedicalCtr https://t.co/CdLx9XO60i
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
RT @JACCJournals: New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly i…
New insights from the @TuftsMedicalCtr hypertrophic #cardiomyopathy registry suggest modern therapies can significantly improve survival. https://t.co/rNby1gef7R #JACC https://t.co/bz7e0d36VB
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction | JACC: Journal of the American College of Cardiology https://t.co/c4KQvDUGU3
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
RT @JTLLERGO: Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant a…
Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction 📍 ICDs and heart transplant are associated with significantly lower mortality 📍 ICDs should be considered when EF is <50% @secardiologia https://t.co/ruWAgs